The proteasome inhibitor Bortezomib, which exerted its antileukemic action through Notch1 downregulation, acted additively in combination with 4-hydroxycyclophosphamide in T-ALL cell models [382]. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.